Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis/macrophage activation syndrome: A systematic review
European Journal of Haematology · 2023
DOI: 10.1111/ejh.14029 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift European Journal of Haematology, 2023. Verfasst von James E G Charlesworth und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. Hauptthemen laut MEDLINE: Lymphohistiocytosis, Hemophagocytic, Macrophage Activation Syndrome, Sepsis, Rheumatic Diseases. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 83 Literaturangaben.
Abstract (Originalsprache)
Background
Haemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS) has a potentially high mortality rate. Anakinra, an interleukin‐1 receptor antagonist, is now recommended early in HLH/MAS, with intravenous (IV) use proposed in critically unwell patients. This systematic review establishes the literature relating to IV anakinra in secondary HLH/MAS (sHLH/MAS).
Methods
We screened Embase, PubMed, and Medline, including all reports of IV anakinra for HLH or MAS. We extracted age, HLH/MAS trigger, continuous infusion or bolus dosing, and survival.
Results
Twenty‐nine case reports/series identified 87 patients (median age 22 years, range 22 months to 84 years), all with sHLH. Amongst identifiable triggers, 43% were systemic infection, 33% rheumatological, 9% oncological. Children had predominantly a rheumatological trigger (48%), whilst adults were more commonly infection‐driven (50%). Overall, rheumatologically triggered disease showed greater survival (83.3%), particularly compared with oncological triggers (42.9%). Children had a greater survival, particularly under 10 years (83%, vs. adults, 63%).
Conclusions
Despite IV anakinra recipients likely to be critically unwell, this cohort had similar disease triggers and survival compared to large historical cohorts, and enhances awareness of age and trigger‐specific survival patterns. IV anakinra had a wide therapeutic dosing range and tolerability, regardless of trigger, demonstrating substantial utility in severe sHLH/MAS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Paediatrics, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
- Paediatric Rheumatology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
ORCID-Profile: James E G Charlesworth
Zitieren
APA
Charlesworth, J. E. G., & Kavirayani, A. (2023). Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis/macrophage activation syndrome: A systematic review. European Journal of Haematology. https://doi.org/10.1111/ejh.14029
Vancouver
Charlesworth JEG, Kavirayani A. Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis/macrophage activation syndrome: A systematic review. European Journal of Haematology. 2023. doi:10.1111/ejh.14029
BibTeX
@article{Charlesworth2023,
author = {Charlesworth, James E G and Kavirayani, Akhila},
title = {Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis/macrophage activation syndrome: A systematic review},
journal = {European Journal of Haematology},
year = {2023},
doi = {10.1111/ejh.14029}
}
EUVIMED